FRNM Freenome, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 2017526 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $183.49M | — | — | — | $1.03M | — | — | — |
| Cost of revenue | $478,000 | — | — | — | $611,000 | — | — | — |
| Gross profit | $183.01M | — | — | — | $424,000 | — | — | — |
| R&D expense | $68.42M | — | — | — | $50.63M | — | — | — |
| SG&A expense | $44.63M | $941,325 | — | -$38.09M | $15.05M | $193,196 | — | — |
| Operating income | $69.97M | -$941,325 | -$858,834 | -$1.68M | -$65.26M | -$193,196 | -$255,958 | -$175,926 |
| Interest expense | $1.19M | — | — | — | $644,000 | — | — | — |
| Net income | $60.11M | -$69.03M | -$63.56M | -$740,568 | -$64.47M | -$58.73M | -$57.87M | $841,432 |
| EBITDA | $75.67M | — | — | — | -$59.46M | — | — | — |
| EPS (basic) | 0.60 | — | — | — | -0.95 | — | — | — |
| EPS (diluted) | 0.58 | — | — | — | -0.95 | — | — | — |
| Weighted avg. shares (diluted) | 103.22M | — | — | — | 68.02M | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $180.38M | $437,369 | $567,179 | $78.56M | $73.98M | $1.34M | $1.19M | $76.17M |
| Receivables | $8.82M | — | — | $1.31M | — | — | — | — |
| Inventory | $1.89M | — | — | $0 | — | — | — | — |
| Current assets | $460.99M | $742,154 | $649,657 | $226.49M | $1.26M | $1.47M | $1.34M | $1.24M |
| PP&E, net | $154.54M | — | — | $155.78M | — | — | — | — |
| Goodwill | $10.51M | — | — | $10.51M | — | — | — | — |
| Intangibles | $2.49M | — | — | $3.30M | — | — | — | — |
| Total assets | $733.53M | $85.83M | $93.33M | $507.05M | $92.20M | $91.40M | $90.63M | $89.90M |
| Current liabilities | $36.20M | $3.63M | $2.86M | $40.53M | $934,557 | $281,154 | $265,572 | $210,811 |
| Total liabilities | $252.20M | $7.08M | $6.31M | $406.61M | $4.38M | $3.73M | $3.72M | $3.66M |
| Shareholders' equity | $481.33M | -$26.61M | $39.68M | $100.44M | $135.69M | $197.05M | $252.92M | $308.56M |
| Shares outstanding | 110.87M | — | — | 67.94M | — | — | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$58.27M | -$129,810 | -$297,852 | -$312,878 | -$166,500 | -$147,528 | -$237,747 | -$79,769 |
| Investing cash flow | -$132.68M | $8.16M | $0 | $0 | $0 | $300,000 | $300,000 | $0 |
| Financing cash flow | $293.66M | — | — | $0 | $0 | — | — | $0 |
| Depreciation & amortization | $5.70M | — | — | — | $5.80M | — | — | — |
| Stock-based compensation | $41.94M | — | — | — | $2.83M | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.